Shandong Wohua Pharmaceutical Co., Ltd. (SHE:002107)
China
· Delayed Price · Currency is CNY 7.00
+0.04 (0.57%)
Mar 10, 2026, 3:04 PM CST
SHE:002107 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 812.08 | 758.76 | 905.1 | 1,013 | 941.8 | Upgrade
|
| Other Revenue | 4.87 | 5.04 | 4.4 | 1.89 | 0.88 | Upgrade
|
| Revenue | 816.95 | 763.79 | 909.51 | 1,015 | 942.67 | Upgrade
|
| Revenue Growth (YoY) | 6.96% | -16.02% | -10.38% | 7.65% | -6.30% | Upgrade
|
| Cost of Revenue | 203.07 | 210.83 | 234.75 | 255.27 | 214.94 | Upgrade
|
| Gross Profit | 613.89 | 552.97 | 674.76 | 759.55 | 727.74 | Upgrade
|
| Selling, General & Admin | 473.38 | 463.38 | 569.12 | 588.31 | 473.06 | Upgrade
|
| Research & Development | 36.39 | 40.65 | 45.35 | 50.11 | 47.48 | Upgrade
|
| Other Operating Expenses | 14.35 | 12.9 | 15.19 | 17.6 | 16.14 | Upgrade
|
| Operating Expenses | 524.46 | 515.9 | 627.71 | 657.74 | 535.77 | Upgrade
|
| Operating Income | 89.43 | 37.06 | 47.05 | 101.81 | 191.97 | Upgrade
|
| Interest Expense | -0.06 | -0.02 | -0.04 | -0.03 | -4.7 | Upgrade
|
| Interest & Investment Income | 5.81 | 4.93 | 5.23 | 4.67 | 6.79 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.41 | -2.94 | -0.82 | -1.65 | -1.16 | Upgrade
|
| EBT Excluding Unusual Items | 98.58 | 39.04 | 51.43 | 104.81 | 192.91 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -13.54 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 2.15 | - | Upgrade
|
| Asset Writedown | -0.17 | -0.03 | -0.06 | -0.44 | -0.02 | Upgrade
|
| Legal Settlements | -1.29 | -0.13 | -0.14 | -0.26 | -0.53 | Upgrade
|
| Other Unusual Items | 5.26 | 3.77 | 3.41 | 4.54 | 11.13 | Upgrade
|
| Pretax Income | 102.38 | 42.65 | 54.64 | 110.79 | 189.96 | Upgrade
|
| Income Tax Expense | 13.59 | 8.89 | 8.01 | 20.91 | 28.63 | Upgrade
|
| Earnings From Continuing Operations | 88.79 | 33.76 | 46.63 | 89.89 | 161.32 | Upgrade
|
| Minority Interest in Earnings | 6.92 | 2.64 | 12.14 | 17.5 | 2.07 | Upgrade
|
| Net Income | 95.72 | 36.4 | 58.77 | 107.39 | 163.39 | Upgrade
|
| Net Income to Common | 95.72 | 36.4 | 58.77 | 107.39 | 163.39 | Upgrade
|
| Net Income Growth | 162.93% | -38.05% | -45.27% | -34.28% | -8.66% | Upgrade
|
| Shares Outstanding (Basic) | 563 | 607 | 588 | 565 | 584 | Upgrade
|
| Shares Outstanding (Diluted) | 563 | 607 | 588 | 565 | 584 | Upgrade
|
| Shares Change (YoY) | -7.20% | 3.24% | 3.98% | -3.15% | 1.13% | Upgrade
|
| EPS (Basic) | 0.17 | 0.06 | 0.10 | 0.19 | 0.28 | Upgrade
|
| EPS (Diluted) | 0.17 | 0.06 | 0.10 | 0.19 | 0.28 | Upgrade
|
| EPS Growth | 183.33% | -40.00% | -47.37% | -32.14% | -9.68% | Upgrade
|
| Free Cash Flow | 127.66 | 87.69 | 126.53 | 178.49 | 181.04 | Upgrade
|
| Free Cash Flow Per Share | 0.23 | 0.14 | 0.21 | 0.32 | 0.31 | Upgrade
|
| Dividend Per Share | 0.266 | - | 0.250 | - | 0.260 | Upgrade
|
| Gross Margin | 75.14% | 72.40% | 74.19% | 74.85% | 77.20% | Upgrade
|
| Operating Margin | 10.95% | 4.85% | 5.17% | 10.03% | 20.36% | Upgrade
|
| Profit Margin | 11.72% | 4.77% | 6.46% | 10.58% | 17.33% | Upgrade
|
| Free Cash Flow Margin | 15.63% | 11.48% | 13.91% | 17.59% | 19.20% | Upgrade
|
| EBITDA | 120 | 69 | 79.57 | 136.79 | 225.02 | Upgrade
|
| EBITDA Margin | 14.69% | 9.03% | 8.75% | 13.48% | 23.87% | Upgrade
|
| D&A For EBITDA | 30.57 | 31.93 | 32.52 | 34.99 | 33.05 | Upgrade
|
| EBIT | 89.43 | 37.06 | 47.05 | 101.81 | 191.97 | Upgrade
|
| EBIT Margin | 10.95% | 4.85% | 5.17% | 10.03% | 20.36% | Upgrade
|
| Effective Tax Rate | 13.27% | 20.84% | 14.66% | 18.87% | 15.07% | Upgrade
|
| Revenue as Reported | 816.95 | 763.79 | 909.51 | 1,015 | 942.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.